Search results
Results from the WOW.Com Content Network
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
The word chemotherapy without a modifier usually refers to cancer treatment, but its historical meaning was broader. The term was coined in the early 1900s by Paul Ehrlich as meaning any use of chemicals to treat any disease ( chemo - + -therapy ), such as the use of antibiotics ( antibacterial chemotherapy ). [ 194 ]
Surgical removal of the prostate, or prostatectomy, is a common treatment either for early-stage prostate cancer or for cancer that has failed to respond to radiation therapy. The most common type is radical retropubic prostatectomy , when the surgeon removes the prostate through an abdominal incision.
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]
This is undesirable especially when most patients with prostate cancer are old-aged. The response to newer medications, such as enzalutamide and abiraterone , is also variable. [ 1 ] However, recent studies have found out that metronomic chemotherapy using cyclophosphamide was more beneficial with fewer side effects as the therapy uses smaller ...